A phase 1 multinational, multicenter, two-stage clinical trial to determine safety and efficacy of new drug in patients with solid tumors with mutations in the BRAF gene
Latest Information Update: 27 Dec 2023
At a glance
- Drugs UB 941 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 26 Dec 2023 New trial record